Pharmacokinetic/Pharmacodynamic Considerations of Alternate Dosing Strategies of Tocilizumab in COVID-19
- 11 December 2021
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 61 (2) , 155-165
Abstract
Tocilizumab is one of few treatments that have been shown to improve mortality in patients with coronavirus disease 2019 (COVID-19), but increased demand has led to relative global shortages. Recently, it has been suggested that lower doses, or fixed doses, of tocilizumab could be a potential solution to conserve the limited global supply while conferring equivalent therapeutic benefit to the dosing regimens studied in major trials. The relationship between tocilizumab dose, exposure, and response in COVID-19 has not been adequately characterized. There are a number of pharmacokinetic (PK) parameters that likely differ between patients with severe COVID-19 and patients in whom tocilizumab was studied during the US FDA approval process. Likewise, it is unclear whether a threshold exposure is necessary for tocilizumab efficacy. The safety and efficacy of fixed versus weight-based dosing of tocilizumab has been evaluated outside of COVID-19, but it is uncertain if these observations are generalizable to severe or critical COVID-19. In the current review, we consider the potential advantages and limitations of alternative tocilizumab dosing strategies. Leveraging PK models and simulation analyses, we demonstrate that a fixed single dose of tocilizumab 400 mg is unlikely to produce PK exposures equivalent to those achieved in the REMAP-CAP trial, although weight-stratified dosing appears to produce more uniform exposure distribution. Data from current and future trials could provide PK/pharmacodynamic insight to better inform dosing strategies at the bedside. Ultimately, rational dosing strategies that balance available limited supply with patient needs are required.Keywords
All Related Versions
This publication has 49 references indexed in Scilit:
- Drug Dosing Based on Weight and Body Surface Area: Mathematical Assumptions and Limitations in Obese AdultsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2012
- A Guide to Rational Dosing of Monoclonal AntibodiesClinical Pharmacokinetics, 2012
- IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6International Journal of Biological Sciences, 2012
- Evaluation of TNF-α and IL-6 levels in obese and non-obese diabetics: Pre- and postinsulin effectsNorth American Journal of Medical Sciences, 2012
- Therapeutic strategies for the clinical blockade of IL-6/gp130 signalingJournal of Clinical Investigation, 2011
- Estimated Lean Body Mass Is More Appropriate than Body Surface Area for Scaling Glomerular Filtration Rate and Extracellular Fluid VolumeNephron Clinical Practice, 2010
- Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti–IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman diseaseBlood, 2008
- High-dose glucocorticoids increase serum levels of soluble IL-6 receptor α and its ratio to soluble gp130: an additional mechanism for early increased bone resorptionEuropean Journal of Endocrinology, 2006
- Soluble Interleukin-6 Receptor in Patients with Severe SepsisThe Journal of Infectious Diseases, 1995
- Prediction of the normal blood volume. Relation of blood volume to body habitus.Circulation, 1977